Marina Gets RNAi Delivery Tools for $5M

7/28/10Follow @xconomy

Marina Biotech (NASDAQ: MRNAD), the Bothell, WA-based company formerly known as MDRNA, has acquired intellectual property rights to a variety of RNA interference drug delivery technologies from Germany-based Novosom. Marina agreed to provide $5 million worth of its common stock in exchange for rights to use Novosom’s liposomal-particle delivery system that’s supposed to get RNA-silencing drugs where they need to go inside cells. This is one of the biggest challenges in the field of RNA interference drug development, as I’ve described in past coverage of Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY) and its delivery partner, Vancouver, BC-based Tekmira Pharmaceuticals.

By posting a comment, you agree to our terms and conditions.